FDA Rejects Neuralink's Human Brain Chip Trials Over Safety Concerns and Animal Welfare Issues

Thumbnail Image

The information displayed in the AIM should not be reported as representing the official views of the OECD or of its member countries.

The FDA rejected Neuralink's application to begin human trials of its AI-powered brain implant, citing major safety concerns such as battery risks, wire migration, and removal complications. The company also faces allegations of animal abuse during development, highlighting significant risks and harm associated with the AI system.[AI generated]

Why's our monitor labelling this an incident or hazard?

The brain implant system developed by Neuralink can be reasonably inferred to involve AI systems due to its advanced neurotechnology and intended autonomous or semi-autonomous functions. The rejection by regulators prevents the system's use or malfunction in humans, so no direct harm has occurred yet. However, the development and regulatory rejection represent a plausible future risk scenario where such AI-enabled implants could lead to harm if tested or deployed prematurely. Since no harm has materialized and the event centers on regulatory decision and potential future risks, this qualifies as an AI Hazard rather than an Incident or Complementary Information.[AI generated]
AI principles
Safety

Industries
Healthcare, drugs, and biotechnology

Affected stakeholders
Consumers

Harm types
Physical (injury)

Business function:
Research and development

AI system task:
Recognition/object detection


Articles about this incident or hazard